Cite
HARVARD Citation
McArthur, G. et al. (n.d.). 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. European journal of cancer. pp. S722-S723. [Online].